Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Center to Find Drug Combinations that Reduce Side Effects
  • USA - English


News provided by

The Mount Sinai Medical Center

Sep 11, 2014, 14:20 ET

Share this article

Share toX

Share this article

Share toX

New York, NY (PRWEB) September 11, 2014 -- A research team from the Icahn School of Medicine at Mount Sinai today received a $12 million grant from the National Institutes of Health to create a center that will screen massive data sets for new uses of existing drugs, and confirm them in human cell tests. The center’s first mission will be to find FDA-approved drugs that reduce side effects when paired with hundreds of leading drugs against common, deadly diseases.

With advances in inexpensive computing power, and stored data collections becoming truly massive in the era of “big data,” researchers are just now able to design algorithms and models that pull previously unrecognized disease and drug treatment patterns from databases. These computational patterns are predictive, and researchers can validate them with experiments.

“The goal of our new center is to detect changes made in human heart, liver and nerve cells as otherwise useful drugs cause side effects, and to find the combinations of existing drugs that reduce these side effects,” said Ravi Iyengar, PhD, the Dorothy H. and Lewis Rosenstiel Professor in the Department of Pharmacology and Systems Therapeutics within the Icahn School of Medicine at Mount Sinai, and the lead investigator for the center grant.

“Our center embodies a third way to reduce the side effects that limit the use of so many treatments, along with two traditional approaches: fine-tuning a drug’s chemical structure or tailoring its use for each individual’s genetics,” he added.

Hidden Signatures
The new grant will fund a Drug Toxicity Signature Generation Center at Mount Sinai as part the NIH Common Fund’s LINCS program, the Library of Integrated Network-based Cellular Signatures program. Each signature is a confirmed set of genetic and protein responses within a type of cell to a drug or drug combination.

The team will find such signatures by combining high-throughput experiments on cell responses to drugs with statistical analyses of side effect, gene and protein interaction databases. Interestingly, the team starts with stem cells and then converts them into the heart, liver and nerve cells used in the experiments. The new center’s goal is to generate 2,000 signatures per year for further testing.

To anchor the signatures to human diseases and treatments, the team will search the U.S. Food and Drug Administration’s Adverse Event Reporting System (FAERS) database to find cases where adding a second drug reduced the side effects associated with a commonly used primary treatment. FAERS has for decades collected such data from individuals, health professionals, drug companies and hospitals, and the millions of records on patients taking multiple drugs now in this public database are free and open to all researchers for analysis.

To translate FAERS-generated drug combinations that reduce toxicity into networks of mechanism-based cell response signatures, the team will then run the experimental results through other databases, including NIH databases of human DNA sequences and interactions between proteins. These networks will be filtered using sophisticated modeling techniques to increase the reliability of the signatures. The most promising signatures can then form the basis for targeted animal and human clinical studies on “drug repurposing.”

The new center will focus on finding drug combinations which reduce side effects that affect the heart (cardiotoxicity), liver (hepatotoxicity) or nervous system (peripheral neuropathy).

“These areas represent the most common and dose-limiting side effects that come with many first-line treatments for heart disease, cancer and diabetes, for instance,” said Dr. Iyengar, who is also Director of the Systems Biology Center New York within the Icahn School of Medicine at Mount Sinai. “While still in the early stages, our efforts have the potential to find second drugs that reduce side effects with a dramatic impact on human health, and in another step toward personalized, precision medicine.”

Along with Dr. Iyengar, the principal investigators for the grant are Marc Birtwistle PhD, Assistant Professor, and Eric Sobie, PhD, Associate Professor, both in the Department of Pharmacology and Systems Therapeutics at Mount Sinai. Christoph Schaniel, PhD, also Assistant Professor in the Department, will lead the efforts to generate heart, liver and nerve cells from human induced pluripotent stem cells taken from normal subjects (healthy organs).

Other Mount Sinai investigators behind the successful grant submission were Milind Mahajan, PhD, in the Department of Genetic and Genomic Sciences and Director of the Genomics Core, James Gallo, PhD, and Avner Schlessinger, PhD, both also in the Department of Pharmacology and Systems Therapeutics. Hong Li, PhD, Director of the Center for Advanced Proteomics at Rutgers New Jersey Medical School will oversee proteomics within the new center.

This center grant is being funded by the NIH Common Fund, which was created by Congress in 2006 to overcome roadblocks in research by funding bold, cross-disciplinary projects with the potential to make leaps and greatly improve human health. Mount Sinai’s center grant will be $2 million per year over the next six years.

The Common Fund supports the LINCS program, which seeks to create a better understanding of human physiology by using a “systems” approach to cataloging changes that occur when cells are exposed to a variety of “perturbing agents,” or agents that change cell function.

About the Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven member hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care.

The System includes approximately 6,600 primary and specialty care physicians, 12-minority-owned free-standing ambulatory surgery centers, over 45 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island, as well as 31 affiliated community health centers. Physicians are affiliated with the Icahn School of Medicine at Mount Sinai, which is ranked among the top 20 medical schools both in National Institutes of Health funding and by U.S. News & World Report.

For more information, visit http://www.mountsinai.org, or find Mount Sinai on Facebook, Twitter and YouTube.

###

Greg Williams, The Mount Sinai Medical Center, +1 (212) 241-9200, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.